New Avenues for Pharma Industry Growth: Dr. HP Tipnis Memorial Lecture

Added:

The Crisis of Affordability and Equity in Advanced Therapeutics

While advanced modalities like cell & gene therapy, mRNA vaccines, and oral biologics represent scientific breakthroughs, critics argue that an overemphasis on these high-tech avenues exacerbates global healthcare inequality. These therapies are exceptionally costly to develop and manufacture, resulting in astronomical price tags that make them inaccessible to patients in low- and middle-income countries, and even strain the public healthcare budgets of wealthy nations. From a public health perspective, prioritizing high-margin, niche biotechnology can divert critical resources and research funding away from affordable essential medicines, preventative primary care, and neglected tropical diseases that affect the global majority. Furthermore, the extreme cold-chain and specialized infrastructure required for mRNA and gene therapies make distribution highly inequitable, highlighting a systemic mismatch between advanced pharmaceutical innovation and global healthcare readiness.

Fundamental principles of molecular biology, specifically the central dogma (DNA to RNA to protein) to understand how mRNA vaccines and gene therapies function.
The basic distinction between small-molecule chemical drugs and complex biologics derived from living organisms.
Human immunology basics, including how the immune system recognizes antigens and the mechanism of action of traditional vaccines.
Gastrointestinal physiology and the concept of the human microbiome, particularly how oral drug delivery is affected by stomach acidity and enzymatic degradation.
Advanced drug delivery systems, specifically the design and application of lipid nanoparticles (LNPs) used to transport mRNA and fragile biologics.
The regulatory, clinical trial, and bioethical frameworks governing the approval of gene therapies and CRISPR-based gene editing.
The bioprocess engineering and cold-chain logistics required to scale up the manufacturing of personalized cell therapies and temperature-sensitive biologics.
The clinical development of Next-Generation Live Biotherapeutic Products (LBPs) and their distinction from commercial over-the-counter probiotics.
142 views2likes2:07:30@bcp_eduOriginal Release: 2021-07-08

The pharmaceutical industry is undergoing a transformative shift toward innovative therapeutic approaches including drug repurposing (reducing development time from 10-17 years to 3-8 years), microbiome-based therapies targeting gut health, oral biologics overcoming gastric instability challenges, mRNA vaccines demonstrating unprecedented rapid development capabilities, cell and gene therapies offering personalized treatment solutions, and precision medicine leveraging individual genetic variability for tailored interventions. These emerging technologies represent significant growth opportunities and require substantial investment in research infrastructure, specialized manufacturing capabilities, and interdisciplinary scientific expertise to translate these innovations into clinical applications that improve patient outcomes.